NASDAQ:EPIX ESSA Pharma Q2 2025 Earnings Report $1.71 -0.04 (-2.29%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.72 +0.01 (+0.58%) As of 07/11/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ESSA Pharma EPS ResultsActual EPS-$0.14Consensus EPS -$0.19Beat/MissBeat by +$0.05One Year Ago EPSN/AESSA Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AESSA Pharma Announcement DetailsQuarterQ2 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETUpcoming EarningsESSA Pharma's Q3 2025 earnings is scheduled for Monday, August 4, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2025 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ESSA Pharma Earnings HeadlinesEPIX | Essa Pharma Inc. Annual Income Statement - MarketWatchJuly 3, 2025 | marketwatch.comESSA Pharma Inc. Explores Strategic Alternatives After Clinical Trial TerminationMay 9, 2025 | tipranks.comYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything… | Crypto 101 Media (Ad)ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025May 8, 2025 | prnewswire.comESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIXMarch 25, 2025 | prnewswire.comEPIX Deadline Today: Rosen Law Firm Urges ESSA Pharma Inc. (NASDAQ: EPIX) Stockholders with Large Losses to Contact the Firm for Information About Their RightsMarch 25, 2025 | businesswire.comSee More ESSA Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ESSA Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ESSA Pharma and other key companies, straight to your email. Email Address About ESSA PharmaESSA Pharma (NASDAQ:EPIX) is a clinical‐stage pharmaceutical company dedicated to developing novel therapies for prostate cancer. The company’s proprietary approach targets the androgen receptor (AR) via its N-terminal domain, a strategy designed to overcome resistance mechanisms that limit current hormone therapies. ESSA’s lead candidate leverages this unique mechanism to address castration‐resistant prostate cancer, positioning the company at the forefront of AR-focused drug discovery. Central to ESSA’s pipeline is its second‐generation AR N-terminal domain inhibitor, which builds on the proof-of-concept established by the company’s first‐generation program. This investigational therapy is engineered to bind a site on the AR that is not addressed by existing treatments, offering potential benefits for patients who have progressed on standard therapies. Ongoing clinical studies are evaluating safety, tolerability and initial efficacy signals in men with advanced prostate cancer. Founded in 2014 and headquartered in Vancouver, Canada, ESSA Pharma also maintains research facilities in the United States to support its global clinical development efforts. The company collaborates with academic institutions and clinical partners across North America and Europe, enrolling patients at leading cancer centers. These partnerships enable ESSA to accelerate trial timelines and broaden access to its investigational agents. ESSA Pharma is led by President and Chief Executive Officer Kelly Martin, Ph.D., whose background spans oncology drug development and strategic biopharmaceutical leadership. The executive team includes seasoned professionals in clinical operations, regulatory affairs and commercial planning, supported by a scientific advisory board composed of experts in prostate cancer biology and translational research.Written by Jeffrey Neal JohnsonView ESSA Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025)ASML (7/16/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
